Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.
about
Marine Natural Products as Models to Circumvent Multidrug ResistanceMarine natural products as breast cancer resistance protein inhibitorsKnocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretionCharacterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).Predicting substrates of the human breast cancer resistance protein using a support vector machine method.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestineBCRP Inhibition: from Data Collection to Ligand-Based Modeling.Role of the breast cancer resistance protein (ABCG2) in drug transport.Metabolism of ATP-binding cassette drug transporter inhibitors: complicating factor for multidrug resistance.The cellular uptake mechanism, intracellular transportation, and exocytosis of polyamidoamine dendrimers in multidrug-resistant breast cancer cells.Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2).Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicityHuman ABCG2: structure, function, and its role in multidrug resistance.ABCG2: recent discovery of potent and highly selective inhibitors.Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells.Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance.ABCG2/BCRP: Specific and Nonspecific Modulators.Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.Exposure of CD34+ precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy.Preferential Langerhans cell differentiation from CD34(+) precursors upon introduction of ABCG2 (BCRP).Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.Transport of gemifloxacin, a 4th generation quinolone antibiotic, in the Caco-2 and engineered MDCKII cells, and potential involvement of efflux transporters in the intestinal absorption of the drug.The colon carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is actively secreted in the distal colon of the rat: an integrated view on the role of PhIP transport and metabolism in PhIP-induced colon carcinogenesis.Optimization of Acryloylphenylcarboxamides as Inhibitors of ABCG2 and Comparison with Acryloylphenylcarboxylates.Acryloylphenylcarboxamides: A New Class of Breast Cancer Resistance Protein (ABCG2) Modulators.Two New Indolyl Diketopiperazines, Trypostatins C and D from Aspergillus penicilliodes Speg.Cariprazine, A Dopamine D₂/D₃ Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer
P2860
Q26741330-1042CC16-B727-4368-9A77-EED096FA1FA4Q27027706-7240F983-4FA6-49D6-A8B0-C6A8A360936EQ28570070-68A719BF-807E-4191-B93E-6B67327EF34CQ33184830-46979FBB-F331-45E9-A461-8F2BF7C11536Q34176588-DD903F32-E756-45CE-A97F-F0D07E69AAD4Q34668324-088FB3D0-B280-4BA4-AC76-A0CCB0C09A9EQ34871636-7BDEB262-82C7-4BE9-854B-EE9FA7CD6245Q35141418-E197576F-7DDE-45DE-A467-694141A491CCQ36093462-9B84EE06-9EBB-466E-82E3-4E7F1BEE1AFFQ36250753-B52E029C-5F87-433A-8E24-4C3CF77D3967Q36572571-9B11BAA2-7EA8-42BE-A206-F5BDC5D3B724Q37158861-0478E325-1A5B-496A-9989-6FF9DAE58BCEQ37560771-486EB716-57E0-40C2-9638-C5A8626FFEEFQ37698421-8A409ED1-B1F2-4BF7-BD3F-8690FA86434FQ38003156-7305845F-CE5C-4190-83A5-6C64E79A1F7BQ38111799-6B0ED83D-1445-426C-8192-8DF05FEB2905Q38818023-BF8FA6EA-0685-4606-8D1F-0CA921105769Q38901400-545FB403-8213-4E9B-A43A-BF6FEE9A6B85Q39049159-7AD4B89C-36FB-4BFF-BB64-8ADA8DD4B7D4Q39392579-C52175C3-9677-4D47-BF3A-E1839F8A3C58Q39482884-0E84FF9F-8A73-46F0-B5EF-D6D525E26C13Q39569136-896EE5D1-35B8-4215-97A3-85956F7EF457Q40722578-699F5FA8-6527-48A4-BA4C-C380064F927BQ42513426-3ADDF42A-0789-45D5-A5C5-03DE05AC4CE8Q42713432-A1E1C6AD-654D-456F-9AD7-CC539C29471CQ51360547-DA634AF2-DDA6-47D2-B913-303A0A45AEA4Q51399264-9F241769-82EE-4B51-BC22-D01CBDBB356DQ52654780-EAAECA3C-39AD-4730-AE6F-D1D74F6A409CQ58764275-BA7D93EC-7088-45A3-B6C1-F967D5B260B4
P2860
Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.
@ast
Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.
@en
type
label
Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.
@ast
Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.
@en
prefLabel
Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.
@ast
Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.
@en
P2093
P1476
Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.
@en
P2093
A H Schinkel
A van Loevezijn
G J Koomen
P356
10.1016/S0960-894X(00)00588-6
P407
P577
2001-01-01T00:00:00Z